PriceTargets.com logo

NuVasive - NUVA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $50.77
  • Forecasted Upside: 36.91%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$37.08 As of 03/24/2023 01:00 AM ET
▲ +0.27 (0.73%)

This chart shows the closing price for NUVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NuVasive Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVA

Analyst Price Target is $50.77
▲ +36.91% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for NuVasive in the last 3 months. The average price target is $50.77, with a high forecast of $58.00 and a low forecast of $44.50. The average price target represents a 36.91% upside from the last price of $37.08.

This chart shows the closing price for NUVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 polled investment analysts is to hold stock in NuVasive. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2023JPMorgan Chase & Co.Boost TargetNeutral$38.00 ➝ $45.00Low
2/23/2023Morgan StanleyBoost TargetEqual Weight$44.00 ➝ $44.50Low
2/10/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$47.00 ➝ $57.72Low
2/10/2023Truist FinancialDowngradeBuy ➝ Hold$51.00 ➝ $52.50Low
2/10/2023CitigroupDowngradeBuy ➝ Neutral$63.00 ➝ $52.00Low
2/9/2023Piper SandlerDowngradeOverweight ➝ NeutralLow
1/31/2023Truist FinancialBoost TargetBuy$48.00 ➝ $51.00Low
1/6/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
11/15/2022Robert W. BairdLower Target$46.00N/A
11/10/2022CowenLower Target$65.00 ➝ $50.00Low
11/10/2022Royal Bank of CanadaLower TargetOutperform$63.00 ➝ $58.00Low
11/10/2022Morgan StanleyLower TargetEqual Weight$48.00 ➝ $44.00Low
11/10/2022Needham & Company LLCLower TargetBuy$53.00 ➝ $52.00Low
11/10/2022CowenLower Target$65.00 ➝ $50.00Low
11/10/2022Wells Fargo & CompanyLower TargetOverweight$62.00 ➝ $47.00Low
11/10/2022Piper SandlerLower TargetOverweight$60.00 ➝ $50.00Low
10/17/2022BarclaysInitiated CoverageOverweight$53.00Low
10/13/2022Robert W. BairdLower Target$54.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageHold$45.00Low
10/7/2022Morgan StanleyLower TargetEqual Weight$54.00 ➝ $48.00Low
10/7/2022Truist FinancialLower TargetBuy$63.00 ➝ $58.00Low
10/7/2022Robert W. BairdLower TargetNeutral$60.00 ➝ $54.00Low
10/5/2022CitigroupLower Target$65.00 ➝ $63.00Low
9/30/2022Needham & Company LLCLower TargetBuy$67.00 ➝ $53.00Low
8/5/2022Canaccord Genuity GroupBoost Target$50.00 ➝ $55.00Low
8/4/2022Piper SandlerLower TargetOverweight$80.00 ➝ $60.00N/A
7/22/2022Truist FinancialLower Target$63.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$62.00 ➝ $54.00Low
4/13/2022Truist FinancialInitiated CoverageBuy$60.00 ➝ $65.00N/A
3/28/2022Wells Fargo & CompanyInitiated CoverageOverweight$58.00High
3/24/2022Needham & Company LLCReiterated RatingBuy$64.00Low
2/24/2022Needham & Company LLCReiterated RatingBuy$64.00High
1/7/2022Morgan StanleyLower TargetEqual Weight$62.00 ➝ $60.00Medium
12/21/2021Truist FinancialLower TargetBuy$75.00 ➝ $60.00High
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$60.00Medium
11/10/2021Truist FinancialLower TargetBuy$80.00 ➝ $75.00High
11/10/2021Credit Suisse GroupLower TargetOutperform$84.00 ➝ $83.00High
11/10/2021UBS GroupLower TargetSell$59.00 ➝ $54.00High
11/10/2021CitigroupLower TargetBuy$82.00 ➝ $70.00High
11/10/2021Needham & Company LLCLower TargetPositive ➝ Buy$73.00 ➝ $64.00High
10/28/2021Loop CapitalInitiated CoverageHoldMedium
10/27/2021Needham & Company LLCLower TargetBuy$80.00 ➝ $73.00Low
10/27/2021JMP SecuritiesReiterated RatingHoldMedium
10/14/2021JPMorgan Chase & Co.Lower TargetNeutral$70.00 ➝ $60.00High
7/29/2021Needham & Company LLCReiterated RatingBuyHigh
5/7/2021Morgan StanleyBoost TargetEqual Weight$70.00 ➝ $74.00Low
5/6/2021Needham & Company LLCBoost TargetBuy$70.00 ➝ $80.00High
5/6/2021Piper SandlerBoost TargetOverweight$75.00 ➝ $80.00High
4/27/2021Truist FinancialBoost Target$68.00 ➝ $80.00High
4/19/2021Morgan StanleyBoost TargetEqual Weight$65.00 ➝ $70.00Low
3/26/2021Piper SandlerBoost TargetOverweight$68.00 ➝ $75.00Low
3/25/2021CitigroupBoost Target$68.00 ➝ $80.00Medium
3/1/2021Piper SandlerBoost Target$63.00 ➝ $68.00Low
3/1/2021Morgan StanleyBoost TargetEqual Weight$53.00 ➝ $65.00Low
1/29/2021Piper SandlerLower TargetOverweight$75.00 ➝ $63.00High
1/6/2021Needham & Company LLCReiterated RatingBuy$74.00N/A
12/16/2020Smith Barney CitigroupUpgradeNeutral ➝ Buy$60.00High
12/15/2020Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $53.00Medium
12/15/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$48.00Medium
11/2/2020Morgan StanleyLower TargetEqual Weight$63.00 ➝ $52.00Medium
10/30/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
10/30/2020SVB LeerinkLower TargetOutperform$70.00 ➝ $65.00High
10/30/2020Robert W. BairdDowngradeOutperform ➝ Neutral$76.00 ➝ $56.00High
10/19/2020Stifel NicolausInitiated CoverageBuy$64.00Low
8/5/2020Northland SecuritiesReiterated RatingHoldHigh
7/21/2020Morgan StanleyReiterated RatingHoldLow
7/21/2020Credit Suisse GroupReiterated RatingBuy$74.00Low
7/20/2020Needham & Company LLCReiterated RatingBuy$74.00High
6/25/2020Northland SecuritiesInitiated CoverageMarket Perform$65.00High
6/23/2020Needham & Company LLCUpgradeHold ➝ Buy$74.00Medium
6/12/2020Credit Suisse GroupReiterated RatingBuy$74.00Low
6/5/2020Wells Fargo & CompanyBoost TargetEqual Weight$62.00 ➝ $63.00High
5/29/2020Credit Suisse GroupReiterated RatingBuy$74.00Medium
5/7/2020Credit Suisse GroupReiterated RatingBuy$74.00High
5/7/2020UBS GroupLower TargetSell$65.00 ➝ $55.00Medium
5/7/2020CitigroupBoost TargetNeutral$55.00 ➝ $58.00Medium
5/7/2020Piper SandlerLower TargetOverweight$90.00 ➝ $75.00Medium
5/4/2020JPMorgan Chase & Co.Lower TargetNeutral$80.00 ➝ $60.00Medium
4/19/2020Robert W. BairdUpgradeNeutral ➝ OutperformMedium
4/14/2020Piper SandlerReiterated RatingBuy$90.00High
4/14/2020Needham & Company LLCReiterated RatingHoldHigh
4/8/2020Wells Fargo & CompanyLower TargetEqual Weight$79.00 ➝ $56.00High
4/8/2020Robert W. BairdUpgradeNeutral ➝ Outperform$82.00 ➝ $66.00High
3/27/2020Morgan StanleyLower TargetEqual Weight$82.00 ➝ $63.00Medium
3/27/2020CitigroupLower TargetNeutral$68.00 ➝ $55.00High
3/6/2020Credit Suisse GroupLower TargetOutperform$92.00 ➝ $86.00High
3/4/2020CitigroupInitiated CoverageNeutral$68.00Medium
2/21/2020Cantor FitzgeraldBoost TargetIn-Line ➝ Neutral$68.00 ➝ $85.00High
2/21/2020Credit Suisse GroupBoost TargetIn-Line ➝ Outperform$87.00 ➝ $92.00High
1/14/2020Robert W. BairdBoost TargetNeutral$74.00 ➝ $82.00Low
1/8/2020Credit Suisse GroupBoost TargetOutperform$76.00 ➝ $87.00Low
1/7/2020SunTrust BanksInitiated CoverageBuy$93.00Low
1/2/2020Piper Jaffray CompaniesReiterated RatingBuy$80.00Low
12/17/2019Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $82.00Low
12/13/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$72.00 ➝ $92.00High
12/12/2019Wells Fargo & CompanyBoost TargetEqual Weight$70.00 ➝ $74.00Low
9/24/2019Royal Bank of CanadaBoost TargetOutperform$74.00Low
9/9/2019UBS GroupBoost TargetSell$51.00 ➝ $55.00Low
8/9/2019CowenSet TargetBuy$75.00Low
8/9/2019BTIG ResearchSet TargetBuy$71.00N/A
8/9/2019BMO Capital MarketsBoost TargetMarket Perform$54.00 ➝ $68.00Low
8/8/2019Needham & Company LLCReiterated RatingHoldLow
8/7/2019Royal Bank of CanadaSet TargetBuy$70.00Low
7/31/2019Piper Jaffray CompaniesSet TargetBuy$72.00Low
7/31/2019Royal Bank of CanadaSet TargetBuy$70.00Low
7/31/2019Morgan StanleyBoost TargetEqual Weight$57.00 ➝ $67.00High
7/29/2019Robert W. BairdDowngradeOutperform ➝ Neutral$66.00Low
7/1/2019BTIG ResearchReiterated RatingBuy$65.00Medium
5/2/2019Cantor FitzgeraldReiterated RatingHold$61.00High
2/12/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$60.00High
2/11/2019Cantor FitzgeraldReiterated RatingHold$50.00High
2/8/2019Needham & Company LLCDowngradeBuy ➝ HoldMedium
1/17/2019BTIG ResearchLower TargetBuy$59.00Medium
1/8/2019UBS GroupLower TargetSell ➝ Sell$54.00 ➝ $42.00Low
1/2/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$73.00 ➝ $57.00Medium
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$66.00High
11/27/2018UBS GroupInitiated CoverageSell$54.00Low
11/27/2018Royal Bank of CanadaBoost TargetOutperform$70.00Low
10/31/2018BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$70.00 ➝ $68.00Low
10/31/2018Morgan StanleyLower TargetEqual Weight ➝ Hold$77.00 ➝ $73.00Low
10/31/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$80.00 ➝ $75.00High
10/19/2018Cantor FitzgeraldReiterated RatingHold$58.00Medium
10/17/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$67.00 ➝ $80.00Medium
9/27/2018Robert W. BairdUpgradeNeutral ➝ Outperform$60.00 ➝ $82.00High
9/25/2018Morgan StanleyBoost TargetEqual Weight ➝ Hold$55.00 ➝ $77.00Low
9/11/2018CowenBoost TargetOutperform$62.00 ➝ $80.00Medium
8/16/2018BTIG ResearchBoost TargetBuy$72.00High
8/14/2018Piper Jaffray CompaniesBoost TargetOverweight$75.00High
8/1/2018Needham & Company LLCLower TargetBuy$69.00 ➝ $67.00High
8/1/2018BTIG ResearchInitiated CoverageBuyHigh
7/31/2018Cantor FitzgeraldReiterated RatingHold$58.00High
6/27/2018Bank of AmericaDowngradeNeutral ➝ UnderperformLow
6/21/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$74.00High
5/31/2018Cantor FitzgeraldInitiated CoverageNeutral$54.00Low
5/2/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$70.00 ➝ $69.00High
5/2/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$69.00High
5/2/2018BTIG ResearchReiterated RatingBuy$72.00High
4/4/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$47.00Medium
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 5 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
10/27/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 10 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2023
  • 10 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 10 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

NuVasive logo
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $37.08
Low: $36.53
High: $37.29

50 Day Range

MA: $43.18
Low: $36.81
High: $48.12

52 Week Range

Now: $37.08
Low: $35.17
High: $60.47

Volume

951,878 shs

Average Volume

1,034,976 shs

Market Capitalization

$1.94 billion

P/E Ratio

52.23

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of NuVasive?

The following sell-side analysts have issued research reports on NuVasive in the last twelve months: Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Cowen Inc, Cowen Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, TheStreet, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for NUVA.

What is the current price target for NuVasive?

14 Wall Street analysts have set twelve-month price targets for NuVasive in the last year. Their average twelve-month price target is $50.77, suggesting a possible upside of 36.9%. Royal Bank of Canada has the highest price target set, predicting NUVA will reach $58.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $44.50 for NuVasive in the next year.
View the latest price targets for NUVA.

What is the current consensus analyst rating for NuVasive?

NuVasive currently has 9 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NUVA, but not buy more shares or sell existing shares.
View the latest ratings for NUVA.

What other companies compete with NuVasive?

Other companies that are similar to NuVasive include AtriCure, Alphatec, Cardiovascular Systems, Orthofix Medical and Integra LifeSciences. Learn More about companies similar to NuVasive.

How do I contact NuVasive's investor relations team?

NuVasive's physical mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company's listed phone number is (858) 909-1800 and its investor relations email address is [email protected] The official website for NuVasive is www.nuvasive.com. Learn More about contacing NuVasive investor relations.